Zecotek Photonics Inc (OTC: ZMSPF) (TSXV: ZMS.V) Breaking News
June 13, 2018

Zecotek Receives Single Largest Purchase Order of $5,000,000 for Patented LFS Scintillation Crystals from Key Distribution Partner

Vancouver, British Columbia --June 13, 2018 - Zecotek Photonics Inc. OTC:ZMSPF) (TSX-V:ZMS) (Frankfurt:W1I) (“Zecotek” or the “Company) a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce the single largest purchase order of $5,000,000 for its patented LFS scintillation crystals through a distribution partner in China. The crystals will be used for positron emission tomography (PET) medical scanning equipment.

“2018 will be a transformative year for Zecotek’s medical imaging business,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “This purchase order of $5 million represents more revenue than we have achieved previously in an entire year. The order also demonstrates the success of the patient and systematic approach we have taken in the Chinese marketplace. Our initiatives have established a strong foothold in China by creating key distribution partnerships, building a talented local sales team, and, as recently announced, installing our own state-of-the-art crystal production facility. The large order comes from one of our key sales channel partners for components related to the PET/CT medical imaging industry. The first shipment of LFS crystals is expected to be completed in the next 30 days, with the crystals coming from our current inventory. The remaining shipments will take place over the next 12 months and will be supplied by our new crystal production facility in Shanghai. We will continue to aggressively expand our sales opportunities in China and elsewhere and look forward to reporting further results.”

Zecotek’s LFS series of scintillation crystals are known to be uniquely qualified for components in PET medical scanners. LFS crystals have the fastest decay parameter in their category, the best energy resolution and competitive pricing, which are key attributes for the new configurations of high resolution Time Of Flight PET scanners. PET OEMs have conducted comparative tests with other many other scintillation materials, and recognize Zecotek’s LFS crystals to be superior for specific designs of PET medical scanners.

Zecotek is focused on of becoming a leading supplier of scintillation crystals and other the key photonic components in China and around the world.

About Zecotek
Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I; OTCPK: ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

SOURCE Zecotek Photonics Inc

Zecotek's Working Closely With European Healthcare OEM as It Prepares to Open Its LFS Crystal Manufacturing Facility

Vancouver, British Columbia --June 11, 2018 - Zecotek Photonics Inc. OTC:ZMSPF) (TSX-V:ZMS) (Frankfurt:W1I) (“Zecotek” or the “Company) a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that it is working closely with a tier 1, healthcare OEM based in Europe to assure quality control protocols within its new Lutetium Fine Silicate (LFS) scintillation crystals manufacturing facility in Shanghai. The healthcare OEM originally ordered LFS crystals for a new line of high resolution positron emission tomography PET/CT medical imaging devices in October 2017. After testing and qualifying Zecotek's arrays produced in China, the healthcare OEM has since made a larger scale order of arrays for final design. The OEM has also deployed personnel to assist with the setup of the crystal growing facility, with higher production volumes to commence later this year.

"We have worked closely with our largest customers to ensure that the LFS scintillation crystals produced in our Shanghai facility meet their exacting standards," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "It is a very exciting time for our Company as we look to begin production of our patented LFS crystals within the next three weeks as site preparation and renovations are now complete. We have benefited from working closely with our customers and specifically the European healthcare OEM, in the setting up of quality control protocols to meet the highest industry standards. We are looking forward to supplying our crystals to the aforementioned European customer as well as other large OEM customers, building high resolution PET machines."

By establishing its own crystal manufacturing facility in Shanghai, the Company is strategically positioning itself to become a dominant supplier. Scintillation crystals play a vital role in fundamental in healthcare, science, industrial and security applications, where they are used to convert high-energy photons into visible light. Zecotek's patented LFS scintillation material with all its variants are known to have superior operating attributes and were developed specifically for use in medical imaging systems, high-energy physics experiments, and other applications.

Zecotek has attracted Chinese and international medical device OEMs, including the tier 1 European OEM adopting LFS crystals, to use the fast and bright LFS scintillation crystals in new generation PET and PET/CT medical scanning devices. New and more efficient readout systems, combined with faster and brighter crystals and more sensitive photo detectors, have created the technological environment where the new devices are being readied for the medical markets with far superior operating systems than current devices being used in hospitals today. Medical officials around the world are seeking faster, higher resolution scanning devices as aging populations place greater demands on their respective healthcare systems.

Zecotek's patented (US patent No. 7,132,060) LFS series of scintillation crystals are characterized by their high light yields and ultra-fast decay times which will produce quicker, more detailed images and diagnoses, resulting in faster patient throughput and improved patient outcomes. The LFS crystals cover a wide range of emission wavelengths which can be tailored to match the spectral sensitivity of various photo detectors including Zecotek's own solid-state MAPD/T photo detector arrays.

Zecotek's manufacturing process uses the Czochralski method with proprietary modifications and results in the growth of very large-diameter boules with uniform properties and without cracking, resulting in high element output and lower unit costs. The crystal manufacturing facility will also provide cutting and polishing producing high quality value-added finished products.

About Zecotek

Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I; OTCPK: ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Shanghai EBO Optoelectronics Technology Co. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

SOURCE Zecotek Photonics Inc

Zecotek Imaging China Retains China-Based Law Firm to Protect Intellectual Property

Vancouver, British Columbia --May 10, 2018 - Zecotek Photonics Inc. OTC:ZMSPF) (TSX-V:ZMS) (Frankfurt:W1I) (“Zecotek” or the “Company) a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that its new subsidiary, Zecotek Imaging China Ltd., has retained the law firm Lexinter Law Group, Shanghai, to safeguard the new manufacturing facility that will produce Zecotek’s patented LFS scintillation crystals in China. With ten offices around the world including Hong Kong and Shanghai, the Lexinter Law Group are experts at protecting intellectual property in any jurisdiction.

“We have retained the Lexinter Law Group to ensure the manufacturing facility for our LFS scintillation crystals in China is secure, protected and is not open to compromise,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “We are very encouraged by the recent comments made by Chinese President Xi Jinping regarding the Chinese economy and enforcement of intellectual property of foreign firms. This reinforces the protection of our patent portfolio surrounding our LFS crystal technology and provides greater confidence to Tier-1 Chinese and international medical device OEM customers operating in and out of China. Most importantly, strong IP regulation together with the best scintillation crystal of its kind, provide for greater sales opportunities for Zecotek. It will facilitate the export of medical scanners by Chinese OEMs which must meet strict international IP requirements. We will protect the integrity of our IP at all times."

Lexinter Law Group is the law firm the world's business leaders from a wide variety of multinational corporations and medium sized enterprises to start-ups, turn to when they want enduring results. The firm has offices in North America, Europe and Asia and is known for protecting intellectual property rights around the world. With a mission to think creatively and proactively in formulating the most effective and efficient solutions to legal needs, Lexinter protects intellectual property rights to create an environment where creativity can flourish and hard work can be rewarded.

About Zecotek
Zecotek Photonics Inc. (TSX-V:ZMS) (Frankfurt:W1I) (OTCPK:ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Shanghai EBO Optoelectronics Technology Co. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com

Source: Zecotek Photonics Inc.
 

Zecotek Prepares to Open LFS Crystal Production Facility in China June 2018

Vancouver, British Columbia --May 08, 2018 - Zecotek Photonics Inc. OTC:ZMSPF) (TSX-V:ZMS) (Frankfurt:W1I) (“Zecotek” or the “Company) a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that its new subsidiary, Zecotek Imaging China Ltd., is moving to open a wholly owned and operated LFS Crystal Production Facility in Shanghai, China in June 2018. Funds from the recent divisional financing of $5 million are being used to prepare the location and acquire the necessary crystal growing ovens and support equipment and personnel. This plant will focus on meeting the significant production and quality demands of Tier 1 customers in China and Europe, and is the result of strong market demand for an integrated production, sales and solutions business model.

“We have worked closely with our customers in China and Europe to determine the best equipment and processes for our new crystal production facility to meet their exacting requirements for high quality LFS crystals and crystal arrays,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “The decision to establish our own crystal production facility was a result of market conditions and lengthy discussions with our main customers to establish high-quality crystals with consistent performance and stable pricing. We are very pleased with our new facility as it provides us with the ability to directly control the quality and cost of our product. The new production facility also allows our patented LFS scintillation crystals to be price and performance competitive at all times, as we cater to new and established customers.”

Site preparations and renovation are underway at Zecotek’s new production facility, and are expected to be complete by June 30, 2018. The plant will begin with sufficient capacity to service existing Tier 1 clients, with expansion plans to carry on in parallel to meet market demands late 2018. The specialized equipment and ovens necessary for growing LFS crystals have been ordered, and are expected to be installed and operational by the end of May 2018, with ISO certification to be completed soon thereafter.

Hiring for the technical and operation team has been initiated and the main crystal growers contracted. Sources for raw materials have been secured and the first delivery of internally manufactured and mass-produced product is scheduled for July 2018.

Cutting, polishing and array assembly will also be moved to Zecotek's new crystal production facility in China. The Company uses a proprietary automated manufacturing process that uses robotics to assemble the LFS crystal arrays. Not only has the automated process translated into faster manufacturing of arrays, it has also improved the performance of the arrays with repeatable uniformity and much greater accuracy.

Zecotek's patented LFS scintillation crystals are grown using the Czochralski method with internal modifications. This proprietary growing method produces very large-diameter boules with uniform properties and without cracking (a problem with many competing scintillation materials). This highly efficient method produces a great number of high quality elements from each boule.

About Zecotek
Zecotek Photonics Inc. (TSX-V:ZMS) (Frankfurt:W1I) (OTCPK:ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Shanghai EBO Optoelectronics Technology Co. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com

Source: Zecotek Photonics Inc.

Zecotek Provides Update for Zecotek Imaging China

Vancouver, British Columbia --April 05, 2018 - Zecotek Photonics Inc. OTC:ZMSPF) (TSX-V:ZMS) (Frankfurt:W1I) (“Zecotek” or the “Company”),

a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that its new subsidiary, Zecotek Imaging China Ltd., has completed the necessary regulatory steps and has establish an office in the Shanghai Technology Zone. The $5 million raised by selling an equity stake in the company based on a $75 million valuation, previously announced on January 31, 2018, has now been released to the new company and is available for deployment.

“We are very pleased to announce the official opening of our new office for Zecotek Imaging China,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “We will now move forward to install our own production facilities for our patented LFS scintillation crystals. It is very important for our Company to gain control over the cost of production to ensure consistency with our customers and supply reliability. The initial focus of the new production facility will be the Chinese and European medical scanning markets.”

Zecotek’s LFS series of scintillation crystals are protected in China and jurisdictions around globe by a worldwide patent (including US patent No. 7,132,060). The crystals cover a wide range of emission wavelengths which can be tailored to match the spectral sensitivity of various photo detectors including Zecotek’s own solid-state MAPD/T photo detector arrays. By using the Czochralski method to manufacture LFS scintillation crystals, Zecotek can grow very large-diameter boules with uniform properties and without cracking (a problem with many competing scintillation materials). Larger, higher quality boules, produce more single elements resulting in greater output with lower unit costs.

About Zecotek
Zecotek Photonics Inc (TSX-V:ZMS) (Frankfurt:W1I) (OTCPK:ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Shanghai EBO Optoelectronics Technology Co. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com

Source: Zecotek Photonics Inc.

Zecotek Signs Agreement with Shanghai Fortune Techgroup to Market and Distribute LFS Crystals in China

Vancouver, British Columbia --March 15, 2018 - Zecotek Photonics Inc. OTC:ZMSPF) (TSX-V:ZMS) (Frankfurt:W1I) (“Zecotek” or the “Company”), a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that it has signed a marketing and distribution agreement with the Shanghai Fortune Techgroup Co. Ltd., a China-based authorized distributor of integrated circuits and related optoelectronic products, to generate sales of its patented LFS crystals to customers in China.

“The Shanghai Fortune Techgroup is a well-established distributor of photonic technologies with customers in China and around the world, and we are very pleased that they will now include our patented LFS scintillation crystals on their product list,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "The partnership with the Fortune Techgroup was prompted by the recent equity investment into Zecotek Imaging China by a local investor, and it complements the existing relationship we have with the Shanghai EBO Optoelectronics Company. Zecotek will be able to leverage their broad networks and experienced sales teams both in and out of China. Furthermore, due to the size and the financial strength of the Fortune Techgroup, Zecotek will also be able to take advantage of more favorable payment terms which will improve cash flow and minimize customer payment risks. With better payment terms offered through distributers, crystal production and handling will be more finely tuned with improved efficiencies. We look forward to initiating production at our new facility and working closely with the Fortune Techgroup to sell our crystals."

Shanghai Fortune Techgroup Co. Ltd. is publicly traded on the Shenzhen Stock Exchange (300493.SZ) with a market cap of approximately $700 million and annual sales of $300 million (2016) from the distribution of a wide range of technical products and support services including integrated circuit application solutions to global customers. There is a natural synergy with Zecotek's LFS crystals and the other optoelectronic products currently distributed by Fortune Techgroup. Fortune group will aggressively market the LFS crystals through its broad sales networks in China and around the globe.

About the Shanghai Fortune Techgroup
Shanghai Fortune Techgroup Co., Ltd., founded in 2000, is the leading provider of semiconductor chips and solutions for telecommunication industry in China. Headquartered in Caohejing Hi-Tech Park, Xuhui District of Shanghai, it has research and development institutions and branches/subsidiaries in Beijing, Shenzhen, Hong Kong and Taiwan.

About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I, OTCPK: ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Shanghai EBO Optoelectronics Technology Co. (China), Beijing Optoelectronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com
 

Source: Zecotek Photonics Inc.

Zecotek Introduces Innovative Wireless ASIC Microchip For Positron Emission Tomography Medical Imaging

Vancouver, British Columbia --March 12, 2018 - Zecotek Photonics Inc. OTC:ZMSPF) (TSX-V:ZMS) (Frankfurt:W1I) (“Zecotek” or the “Company”), a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce a novel wireless full duplex single frequency ASIC microchip to be used in conjunction with the solid-state MAPT photo detectors in high resolution positron emission tomography (PET) medical scanners. Healthcare is one of the top five segments of the global application specific integrated circuit market that researchers project to grow to be valued over U$35 billion by 2024.

“The wireless full duplex single frequency ASIC microchip is our latest component that we have developed for high resolution PET medical imaging,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “Like our LFS scintillation crystals and MAPD and MAPT solid-state photo detectors used in new PET medical scanners, the wireless ASIC was designed to improve the operating efficiency of the imaging devices. The new wireless ASIC will form part of Zecotek’s Integrated Detector Module comprising of a LFS array, MAPT array and read out electronics, offering manufactures a complete modular solution for medical imaging. It is very likely that the performance and cost characteristics of our wireless ASIC can benefit other large and growing markets.”

A significant cost and reliability challenge in high resolution PET/CT medical imaging, is the use of many copper cables and connectors. Higher resolution medical imaging demands a greater number of detector channels required, and the use of convention cabling restricts the physical designs of many of imaging systems, and thus limits their deployment for special imaging needs. With Zecotek’s wireless ASIC for PET medical imaging, the ability of hundreds of detector channels to send data to a central concentrator, through short range very fast RF systems, eliminates much of the cabling required in scanners and frees up constraints on the physical layout of detector arrays.

Zecotek’s new full duplex single frequency ASIC microchip optimizes RF communications to support a wide range of applications: from one-to-one data exchange between two devices, to hundreds of data sources exchanging data with a single data receiver or manager. This full duplex radio approach with a basic protocol will allow developers to custom design how data is packaged and sent between devices, while providing data transfer approaching orders of magnitude faster than what has been achieved with current commercial devices.

About Zecotek
Zecotek Photonics Inc (TSX-V:ZMS)(Frankfurt:W1I)(OTCPK:ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Shanghai EBO Optoelectronics Technology Co. (China), Beijing Optoelectronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com

Source: Zecotek Photonics Inc.

Zecotek Announces Divisional Equity Financing of $5,000,000 Based on $75 Million Valuation

Vancouver, British Columbia --01/31/18 - Zecotek Photonics Inc. OTC:ZMSPF) (TSX-V:ZMS) (Frankfurt:W1I) (“Zecotek” or the “Company”), a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that it has closed on a previously announced divisional equity financing of $5 million.

The financing was completed by selling a 6.67% equity interest in a newly formed, wholly owned subsidiary Zecotek Imaging China Ltd. for net proceeds of $5 million. Zecotek has secured the divisional investment with an industrial business group based in China, which has also made a significant investment in the recently announced non-brokered private placement. The divisional financing was based solely on the appraised pre-commercialized value of Zecotek's patented LFS scintillation crystal technology of approximately $75 million.

"The funds raised by the equity sale in Zecotek Imaging China will be used to enhance the production capacity and sales of our patented LFS scintillation crystals," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "The in-house capacity will allow us to gain full control over the cost and price of our LFS crystals, and set a benchmark and standard to ensure price-performance and supply consistency for our customers. We have made considerable progress in the Chinese marketplace with collaboration and supply agreements with EBO Optoelectronics and have commitments from three medical scanner OEMs to use our LFS crystals. Our own China based operation complements our existing China based manufacturing partnerships and will provide supply assurance for our existing partners as well as immediate European and Chinese medical scanner OEM customers and other LFS crystal users worldwide."

Zecotek is also pleased to announce the formation of a new subsidiary: Zecotek Imaging China Ltd. This wholly owned subsidiary has been established in the Shanghai Technology Zone, and will operate under its parent company Zecotek Imaging Systems Ltd. Zecotek Imaging China will establish a presence in China and around the world through the production and commercialization of Zecotek's patented LFS scintillation crystals in its current and future forms. Zecotek Imaging China will work closely with EBO and its customers within China and the broader international medical imaging market.

About Zecotek

Zecotek Photonics Inc (TSX VENTURE: ZMS)(FRANKFURT: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Shanghai EBO Optoelectronics Technology Co. (China), Beijing Optoelectronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

Source: Zecotek Photonics Inc.

Zecotek Closes Non-Brokered Private Placement

Vancouver, British Columbia --01/29/18 - Zecotek Photonics Inc. OTC:ZMSPF) (TSX-V:ZMS) (Frankfurt:W1I) (“Zecotek” or the “Company”), a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, today announced that the Company has closed its private placement announced on December 29, 2017, by selling 16,103,000 units (each a "Unit") of the Company at a price of $0.30 per Unit for gross proceeds of $4,830,900.

Each Unit of the Company consists of one common share (a "Share") and one common share purchase warrant (a "Warrant"). Each Warrant entitles the holder to acquire one Share at an exercise price of $0.43 per Share for a period of two years from closing.

The Company paid finder's fees consisting of cash fees totalling $98,997.99 and issued 329,993 finder's warrants ("Finder's Warrants") exercisable at a price of Cdn$0.43 per Share for a period of two years from closing.

13,819,666 of the Units and the Finder's Warrants are subject to a four-month hold period expiring on May 26, 2018.

Net proceeds from the funds raised will be used for general working capital purposes including the manufacture of products and strengthening and maintaining the Company's IP portfolio.

About ZecotekZecotek Photonics Inc (TSX VENTURE: ZMS)(FRANKFURT: W1I)(OTC PINK: ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Shanghai EBO Optoelectronics Technology Co. (China), Beijing Optoelectronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

Source: Zecotek Photonics Inc.

Zecotek to Present at the Cantech Investment Conference 2018

Vancouver, British Columbia --01/29/18 - Zecotek Photonics Inc. OTC:ZMSPF) (TSX-V:ZMS) (Frankfurt:W1I) (“Zecotek” or the “Company”), a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce its upcoming attendance at the fifth annual Cantech Investment Conference 2018 on January 31, 2018 at the Metro Toronto Convention Centre.

Investors can attend the Company's corporate presentation at 3:50pm on the Paradigm Innovation Stage.

Investors will have an opportunity to meet Zecotek representatives at the Company's booth (#505) during the day.

About Cantech Investment ConferenceCantech Investment Conference 2018 is Canada's largest technology investment conference, which is expected to bring together over 3,500 attendees and engaged investors with more than 100 leading technology companies. Meeting attendees have invested over $1 billion in Canadian tech companies since the advent of the conference 5 years ago. For more information, please visit www.cambridgehouse.com

Event: Cantech Investment Conference 2018
Date: Wednesday, January 31, 2018
Booth: #505
Feature Presentation: 3:50 pm ET at the Paradigm Innovation Stage
Venue: Metro Toronto Convention Centre, 255 Front Street West, Toronto, Canada.
Event Hours: 8:30am - 5:30pm

About ZecotekZecotek Photonics Inc (TSX VENTURE: ZMS)(FRANKFURT: W1I)(OTC PINK: ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Shanghai EBO Optoelectronics Technology Co. (China), Beijing Optoelectronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com

For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

Source: Zecotek Photonics Inc.

-------------------------------------------------------------------
About Zecotek Photonics Inc:

THE HISTORY OF ZECOTEK
We excel in the innovation and commercialization of key enabling technology, subsystems, and components for medical and industrial imaging, computer generated and real time 3D visualization as well as lasers for bio-pharmaceutical and a wide range of scientific research and industrial applications.

OUR HISTORY
Zecotek Photonics Inc. is a public company founded by Dr. A. F. Zerrouk in December 2004, in an effort to fund the final phase of research and development of an array of photonics technologies and their transfer to manufacturing and commercialisation.Dr. Zerrouk brings to the company a wealth of knowledge and experience in the photonics industries. In 1989, he established the first foreign partnered, private, business oriented photonics research Lab in the Ex-Soviet Union (Novosibirsk, Siberia). He duplicated the same model in three prestigious research institutes in Moscow. Dr. Zerrouk has acted as a technology transfer advisor, working closely with the Ministry of Science and Technology during the transition period to the Russian federation. He worked on Research and Development strategies for the new economy with prominent members of the Russian Academy of Science and coordinated many government projects in joint relations between Russia and countries like China, Germany, USA, Malaysia, and Saudi Arabia.

Dr. Zerrouk was Chairman and CEO of various companies in Europe and Asia. He has held research and faculty positions at various centers: the Clarendon Laboratory, University of Oxford, England, (Atomic & Laser physics); Siberian Academy of Sciences (TOKAMAK and Laser fusion research); the Institute of Thermal Processes, Moscow (high-power gas dynamic lasers) and the Institute of General Physics, Moscow.

In December 2004, Zecotek’s new, wholly owned subsidiary, Zecotek Crystals Inc., acquired from Zecotek Holdings Inc. the intellectual property and know-how, associated with a new and proprietary scintillation crystal (“LFS”) that emits blue light and is a key component in the design of whole body positron emission tomograph (“PET”) scanners.

In early 2006, the senior management team determined it could derive superior returns and increased shareholder value through the integration of its various technologies into higher value-added components and the selective production of finished product. Following this decision, several sites for the establishment of manufacturing and commercialization facilities were evaluated, with Singapore and Malaysia eventually chosen.

In April 2006, Zecotek incorporated a new, wholly owned subsidiary in Singapore. For strategic, operational and financial efficiencies the Singapore operations have been organized into three separate and distinct divisions; Zecotek Imaging Systems, Zecotek Display Sytems and Zecotek Laser Systems. The Singapore operations will continue to be supported by Zecotek related laboratories in Russia and Canada, as well as collaboration partners in the U.S and Canada, and by project management and market development from North America and Europe – much of which will also qualify for grant support from Singapore.

MAPD PHOTODETECTOR ARRAYS & SINGLE ELEMENTS
Zecotek has developed a new compact and cost effective photo detector for low light detection. Our new approach will phase out bulky and expensive PMT's, offering compact and cost effective solutions that can operate in the harshest conditions.

AN ARRAY OF POSSIBILITIES
With our cutting edge automated technique we can produce arrays with unmatched uniformity and precision resulting in better detector matching and performance. Find out what we can do for you.

LFS SCINTILLATION CRYSTALS
Zecotek’s LFS scintillation crystals are distinguished by their combined high light yields and ultra-fast decay constant, covering a wide range of emission wavelengths, that set them apart from other industry contenders.

WHAT MAKES OUR ARRAYS DIFFERENT?
Traditionally arrays are assembled by hand. Fabricated from individual elements, wrapped and organized one at a time into a matrix of desired dimensions, this technique is costly, time consuming and leaves large margins for error and misalignment.

One of the keys to achieving higher resolution and in general more accurate and precise results from your imaging setup is correct matching of array to detector. With our specialized automated process, arrays can now be assembled robotically with greater accuracy, repeatability and uniformity.

Our arrays are produced in a fraction of the time required by traditional processes, are more cost effective and have better detector matching characteristics. Zecotek invites you to experience improved turn around time, lower cost and higher accuracy with our unique LFS scintillation crystal arrays.

SOURCE: http://zecotek.com/

Disclaimer